In the immuno-oncology rivalry between Merck’s Keytruda and Bristol-Myers Squibb’s Opdivo, Keytruda has been running the table. But Opdivo boasts the latest…

A set of women claiming Pfizer’s blockbuster statin Lipitor caused their diabetes have the right to go back to California state court to make their case.

A Sanofi executive has explained the rationale behind the company’s Zika vaccine development plan and is issuing a defense against claims his company is out to…

Roche’s new drug Ocrevus has landed in the same sentence with the three letters all makers of multiple sclerosis drugs dread: PML.

In one CEO popularity contest, biopharma chiefs are pretty average. But some top execs, including CEOs at Roche, AbbVie and Merck & Co., won kudos.…

The already embattled Valeant has no interest in footing the bill for liability lawsuits over the talc products it bought from J&J.

Inovio is getting closer to producing an effective HIV vaccine. Data from an early-stage clinical study showed that its Pennvax-GP could elicit almost 100%…

Just days after announcing plans to ax 500 jobs in Switzerland, Novartis said another 250 jobs will be eliminated in the U.S.

Neurocrine’s Ingrezza, fresh off its first FDA approval and aiming for another, just hit a major roadblock.

Pharma